TY - JOUR
T1 - Ganglioside GD2 in small cell lung cancer cell lines
T2 - Enhancement of cell proliferation and mediation of apoptosis
AU - Yoshida, Shoko
AU - Fukumoto, Satoshi
AU - Kawaguchi, Haruhiko
AU - Sato, Shigeki
AU - Ueda, Ryuzo
AU - Furukawa, Koichi
PY - 2001/5/15
Y1 - 2001/5/15
N2 - Expression levels of gangliosides and glycosyltransferase genes responsible for their syntheses in human lung cancer cell lines and a normal bronchial epithelial cell line were analyzed. Both non-small cell lung cancers and small cell lung cancers (SCLCs) mainly expressed GM2 and GM1, whereas only SCLCs expressed b-series gangliosides, such as GD2, GD1b, and GT1b. Accordingly, many SCLC cell lines showed up-regulation of the GD3 synthase gene. Consequently, we introduced GD3 synthase cDNA into a SCLC line with low expression of b-series gangliosides and analyzed the effects of newly expressed gangliosides on tumor phenotypes. The transfectant cells expressing high levels of GD2 and GD3 exhibited markedly increased growth rates and strongly enhanced invasion activities. Addition of anti-GD2 monoclonal antibodies into the culture medium of these cells resulted in the marked growth suppression of GD2-expressing cell lines with reduced activation levels of mitogen-activated protein kinases but not of nonexpressants, suggesting that GD2 plays important roles in cell proliferation. Moreover, GD2-expressing cells treated with anti-GD2 antibodies showed features of apoptotic cell death at 30 min after addition of antibodies, i.e., shrinkage of cytoplasm, binding of Annexin V, and staining with propidium iodide, followed by DNA fragmentation. This GD2-mediated apoptosis was associated with caspase-3 activation and partly inhibited by a caspase inhibitor, z-Val-Ala-Asp-fluoromethyl ketone. The finding that anti-GD2 antibodies suppressed the cell growth and induced apoptosis of SCLC cells strongly suggested the usefulness of GD2 as a target for the therapy of disastrous cancer, although the precise mechanisms for apoptosis remain to be clarified.
AB - Expression levels of gangliosides and glycosyltransferase genes responsible for their syntheses in human lung cancer cell lines and a normal bronchial epithelial cell line were analyzed. Both non-small cell lung cancers and small cell lung cancers (SCLCs) mainly expressed GM2 and GM1, whereas only SCLCs expressed b-series gangliosides, such as GD2, GD1b, and GT1b. Accordingly, many SCLC cell lines showed up-regulation of the GD3 synthase gene. Consequently, we introduced GD3 synthase cDNA into a SCLC line with low expression of b-series gangliosides and analyzed the effects of newly expressed gangliosides on tumor phenotypes. The transfectant cells expressing high levels of GD2 and GD3 exhibited markedly increased growth rates and strongly enhanced invasion activities. Addition of anti-GD2 monoclonal antibodies into the culture medium of these cells resulted in the marked growth suppression of GD2-expressing cell lines with reduced activation levels of mitogen-activated protein kinases but not of nonexpressants, suggesting that GD2 plays important roles in cell proliferation. Moreover, GD2-expressing cells treated with anti-GD2 antibodies showed features of apoptotic cell death at 30 min after addition of antibodies, i.e., shrinkage of cytoplasm, binding of Annexin V, and staining with propidium iodide, followed by DNA fragmentation. This GD2-mediated apoptosis was associated with caspase-3 activation and partly inhibited by a caspase inhibitor, z-Val-Ala-Asp-fluoromethyl ketone. The finding that anti-GD2 antibodies suppressed the cell growth and induced apoptosis of SCLC cells strongly suggested the usefulness of GD2 as a target for the therapy of disastrous cancer, although the precise mechanisms for apoptosis remain to be clarified.
UR - http://www.scopus.com/inward/record.url?scp=0035872467&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035872467&partnerID=8YFLogxK
M3 - Article
C2 - 11358851
AN - SCOPUS:0035872467
SN - 0008-5472
VL - 61
SP - 4244
EP - 4252
JO - Cancer Research
JF - Cancer Research
IS - 10
ER -